Biogen

Biogen develops, manufactures and markets therapies for patients living with serious neurological, autoimmune and hematologic disorders. Read more

11,682 Followers on Owler
11,682 Followers on Owler
11,682 Followers on Owler
11,682 Followers on Owler

Biogen

Biogen develops, manufactures and markets therapies for patients living with serious neurological, autoimmune and hematologic disorders. Read more

Michel Vounatsos's photo - CEO of Biogen

CEO

Michel Vounatsos

CEO Approval Rating

52/100

Founded:

1978

Status:

PublicIndependent CompanyNASDAQBIIB

BIOGEN TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Sanofi is perceived as one of Biogen's biggest rivals. Sanofi's headquarters is in Paris, Île-de-France, and was founded in 1994. Sanofi operates in the Pharmaceuticals industry. Sanofi generates 330% of Biogen's revenue.

Bayer has been one of Biogen's top competitors. Bayer is a Public company that was founded in 1863 in Leverkusen, North Rhine-Westphalia. Bayer is in the Medical Research & Laboratories field. Compared to Biogen, Bayer has 91,738 more employees.

TEVA is Biogen's #3 rival. TEVA was founded in Petach Tikva, Center District} in 1901. TEVA operates in the Pharmaceuticals industry. Compared to Biogen, TEVA generates $2.9B more revenue.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is EMD Serono a competitor of Biogen?

Biogen Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$13.4B

Biogen's revenue is the ranked 17th among it's top 10 competitors. The top 10 competitors average 25.5B. Over the last four quarters, Biogen's revenue has decreased by 19.3%. Specifically, in Q4 2020's revenue was $2.9B; in Q3 2020, it was $3.4B; in Q2 2020, it was $3.7B; in Q1 2020, Biogen's revenue was $3.5B.

Biogen Acquisitions

COMPANY ACQUIRED
ACQUISITION DATE
AMOUNT
DESCRIPTION
Nightstar Therapeutics Plc

Mar 2019

Source »
$800M
Nightstar develops novel therapies for the treatment of rare inherited retinal diseases.

These are all the companies that Biogen has acquired. Biogen's latest acquisition was Nightstar Therapeutics Plc in Mar 2019. Nightstar develops novel therapies for the treatment of rare inherited retinal diseases.

Biogen Funding History

No recent funding data found related to Biogen

Biogen Investments

COMPANY

DESCRIPTION

AMOUNT

INVESTMENT DATE

ROUND

EXIT DATE

Autobahn Therapeutics develops and commercializes regenerative medicines for the treatment of central nervous system disorders.
$76M
Jun 08, 2020
Series B
-
Samsung Bioepis develops and produces biopharmaceutical and biosimilar products.
$673.4M
Jul 28, 2018
Equity
-
Solid Biosciences develops and commercializes gene therapies for the treatment of Duchenne muscular dystrophy disorder.
$50M
Mar 29, 2017
Series C
Jan 25, 2018
Yumanity Therapeutics develops and commercializes drug-based therapies for the treatment of neurodegenerative diseases.
$51M
Feb 07, 2016
Series A
-
Rodin is a biotechnology company that discovers, develops and commercializes therapeutics for the treatment of neurologic diseases.
$17.3M
Jan 05, 2016
Equity
Nov 01, 2019

These are all the companies that Biogen has invested in. Biogen's latest investment was Nightstar Therapeutics Plc in Mar 2019. Nightstar develops novel therapies for the treatment of rare inherited retinal diseases.

Biogen News

April 28, 2021Markets Insider

Biogen Provides Regulatory Update on the Supplemental Biologic License Application (sBLA) for Subcutaneous Administration of TYSABRI (natalizumab)

CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that ... See more »
April 27, 2021The Business Journals

After pressure, Biogen to expand compassionate use for ALS drug

Following pressure by advocates for patients with amyotrophic lateral sclerosis, or ALS, Biogen has e... See more »
April 27, 2021Endpoints News

Biogen's Michel Vounatsos takes home $18.7M in pay as the company battles to take aducanumab to market

Biogen found itself at the center of controversy late last year as it worked with the FDA to grease t... See more »
April 26, 2021The Business Journals: Boston

Biogen CEO nets highest-ever pay for second year in a row

For the second year in a row, Biogen CEO Michel Vounatsos has nabbed his highest-ever compensation, e... See more »
April 23, 2021Pharmaceutical Processing World

Biogen Q1 earnings beat estimates, raises EPS guidance

Biogen (NASDAQ: BIIB) posted first-quarter results that beat the Wall Street consensus forecast, with... See more »
April 22, 2021The Pharma Letter

Biogen beats expectations, despite 24% sales dive

US biotech major Biogen today reported first quarter 2021 financial results which, though well below.... See more »
April 22, 2021Benzinga

Biogen's Shares Are Trading Lower On 71% Quarterly Profit Slump, Weak Tecfidera Sales

Biogen Inc (NASDAQ: BIIB) reported a 70.7% fall in Q1 profit as its top-selling multiple sclerosis dr... See more »

Biogen Press Releases

February 5, 2021CSRwire

Biogen Offers Arcadia's Home Renewable Energy Program to Employees

Arcadia, a monthly subscription service that connects renters and homeowners across the US to wind an... See more »
January 11, 2021NewsFile

January 12, 2021

New York, New York--(Newsfile Corp. - January 11, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies... See more »
December 17, 2020StreetInsider

Pharma Giant And Speciality Pharmacy Settle Case Alleging False Claims Violations

BOSTON, Dec. 17, 2020 /PRNewswire/ -- One of the world's largest pharmaceutical companies, Biogen, In... See more »
December 16, 2020NewsFile

Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB

New York, New York--(Newsfile Corp. - December 16, 2020) - Pomerantz LLP is investigating claims on b... See more »
December 8, 2020GlobalNewswire

Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB

NEW YORK, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of invest... See more »
December 4, 2020Business Wire

December 7, 2020

NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action ... See more »

Biogen Videos

Social Media

Biogen Headquarters

225 Binney Street

Cambridge, Massachusetts02142

781-464-2000

Driving Directions »

Trending Companies

Biogen Summary

ABOUT

Overview

Biogen develops, manufactures and markets therapies for patients living with serious neurological, autoimmune and hematologic disorders. Biogen was founded in 1978. Biogen's headquarters is located in Cambridge, Massachusetts, USA 02142. Biogen's late...

CEO

Biogen's CEO, Michel Vounatsos, currently has an approval rating of 52%. Biogen's primary competitors are Sanofi, Bayer & TEVA.

Website

biogen.com

Frequently Asked Questions about Biogen

  1. When was Biogen founded?

    Biogen was founded in 1978
  2. Who is Biogen's CEO?

    Biogen's CEO is Michel Vounatsos
  3. How much revenue does Biogen generate?

    Biogen generates $13.4B in revenue
  4. How much funding does Biogen have?

    Biogen has historically raised $0 in funding
  5. Where is Biogen's headquarters?

    Biogen's headquarters is in Cambridge Massachusetts, USA
  1. How many employees does Biogen have?

    Biogen has 7,800 employees
  2. What sector does Biogen operate in?

    Biogen is in Biotechnology
  3. Who are Biogen's competitors?

    Biogen's top competitors are Sanofi, Bayer, TEVA
  4. Who has Biogen invested in?

    Biogen's has invested in companies such as Autobahn, Samsung Bioepis, Solid Biosciences